Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKalil (ACTT-3), 2021 (REV) 0.57 [0.17; 1.96] 0.57[0.17; 1.96]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable deathsdetailed resultsKalil (ACTT-3), 2021 (REV) 0.57 [0.17; 1.96] 0.57[0.17; 1.96]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable deaths (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 (REV) 0.57 [0.17; 1.96] 0.57[0.17; 1.96]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable clinical improvementdetailed resultsKalil (ACTT-3), 2021 (REV) 1.01 [0.89; 1.15] 1.01[0.89; 1.15]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 (REV) 0.99 [0.78; 1.26] 0.99[0.78; 1.26]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 (REV) 1.01 [0.89; 1.15] 1.01[0.89; 1.15]Kalil (ACTT-3), 2021 (REV)10%969NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-07 17:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons